New stroke treatment aims to bust clots directly in the brain
NCT ID NCT07668323
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether giving clot-busting drugs directly into the blocked brain artery (intra-arterial thrombolysis) helps people recover better from a medium-vessel stroke. About 306 adults aged 18-80 with acute stroke will be randomly assigned to receive either the drug plus standard care or standard care alone. The main goal is to see if more people achieve functional independence (able to carry out daily activities) 90 days after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
clot-busting drugs (alteplase or tenecteplase)
What this could lead to
If it works, this could offer a new treatment option for people with medium-vessel stroke, potentially improving recovery and reducing disability.
What could go wrong
This is an early-stage trial with only 306 participants, so results may not apply to everyone. There is a risk of bleeding or other complications from the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••